ABCC1 and breast carcinoma: Studies reveal that LINC00518, through sequestering miR-199a, augments MRP1 expression, thereby enhancing multidrug resistance to ADR (Adriamycin), VCR (Vincristine), and PTX (Paclitaxel) in breast cancer cells, inhibiting apoptosis, and reducing caspase 9 activity (12).